Photobiomodulation (PBM / Red Light Therapy) for ALS
Also known as: PBM, Low-level light therapy, LLLT, Red light therapy, Near-infrared therapy
Transcranial PBM targets mitochondrial dysfunction in motor neurons by directly stimulating cytochrome c oxidase in the electron transport chain.
Mechanism of Action
Red/NIR photons (670nm, 810nm) are absorbed by cytochrome c oxidase (Complex IV), dissociating inhibitory nitric oxide and increasing electron flow. This boosts ATP production in energy-starved motor neurons, reduces ROS, and activates NF-κB and MAPK signaling cascades that promote cell survival.
General mechanism: Red/NIR photon absorption by cytochrome c oxidase (Complex IV). Boosts ATP, reduces ROS, activates NF-κB/MAPK survival signaling, induces BDNF.
Current Evidence
Preclinical evidence shows motor neuron preservation in ALS models. Case reports and small studies suggest symptomatic benefit. The mechanism is well-characterized. Larger controlled trials are needed.
Clinical Status: FDA-cleared for pain and wound healing. Transcranial PBM for neurological conditions in Phase II trials. Home-use devices available.
Safety Profile
Excellent safety. No significant adverse effects. Non-invasive. Eye protection needed for direct light exposure. Home-use devices widely available.
Key Research Questions
- Can transcranial PBM reach motor neurons in the spinal cord at therapeutic intensities?
- What wavelength and dosing protocol optimizes mitochondrial support in ALS?
- Does combination with CoQ10 or NMN provide additive mitochondrial benefit?